We have added Alexza Pharmaceuticals, Inc. (ALXA): Nasdaq to our featured and our watch list today with the upcoming FDA meeting in October for AZ-004 Staccato loxapine, we ask you to do some research on this company. We just love the pharma tech plays specially the smaller ones as they could have potential for big moves.
Alexza Pharmaceuticals, Inc. (ALXA) : Nasdaq ) Currently trading on the NASDAQ Exchange in the usa, Alexza a development stage company, focuses on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions.
(ALXA) Is trading down today @ $2.52 on news of $18 million in stock and warrants to institutional investors. We believe this will be a great opportunity to buy at a lower price for the FDA run up.
(ALXA) uses its technology, the Staccato system, to deliver aerosolized, excipient-free drugs through the lungs for rapid systemic absorption for the acute treatment of CNS conditions. ALXA’s lead program, AZ-004 (Staccato loxapine) for the acute treatment of agitation in patients with schizophrenia or bipolar disorder, is currently under FDA review.
(ALXA) shares tumbled today from $3.00 to $2.52 in afternoon trading The company has been trading around $3.00 to $2.45 and has a 52 week low of $1.93 and a 52 week high of $3.92.
(ALXA) Successfully completed two Phase 3 trials: a 344-patient trial for schizophrenia and a 314-patient trial for bipolar disorder. Both trials met primary and secondary endpoints. The company submitted an NDA in December 2009.
The possible Upcoming Catalyst for ALXA is AZ-004: PDUFA Oct 11, 2010. NDA accepted Feb 11, 2010 we believe this could or may be a good time to buy ALXA at this price.
(ALXA) Have $41M cash as of June 2010, runway to 2Q11
About Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA)
Alexza Pharmaceuticals is a rapidly emerging pharmaceutical development company focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system, or CNS conditions. All of our product candidates are based on our proprietary technology, the Staccato® system. The Staccato system vaporizes excipient-free drugs to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. Because of the ideal particle size of the aerosol, the pure drug is quickly absorbed through the deep lung into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous (IV) administration but with greater ease, patient comfort and convenience. Alexza currently has five product candidates in various stages of clinical development, and one product candidate for which clinical trials have been completed and an NDA has been submitted.
Investor Relations:
August Moretti
Senior Vice President and
Chief Financial Officer
Phone: 650-944-7000
Pennystockpicksus may feature companies for informational and research purposes only and does not recommend you Buy or Sell any companies we feature or list on our website.
Please read our disclaimer at the top of the page.
Pennystockspicksus has received no compensation for this feature.
Article by http://www.pennystockpicksus.com (c)
Pennystockspicksus have taken a long position as of today. Closed out long position 22/09/2010 for a huge $0.96 gain.